Abstract: Improvement of scintigraphic tumor imaging is extensively determined by the development of more tumor specific radiopharmaceuticals. Thus, to improve the differential diagnosis, prognosis, planning and monitoring of cancer treatment, several functional pharmaceuticals have been developed. The application of molecular targets for cancer imaging, therapy and prevention using generator-produced isotopes is the major focus of many ongoing research projects. Radionuclide imaging modalities (single photon emission computed tomography, SPECT; positron emission tomography, PET) are diagnostic cross-sectional imaging techniques that map the location and concentration of radionuclide-labeled radiotracers. Generator produced isotopes, such as 99m Tc and 68 Ga, are readily available and affordable.
DEVELOPMENT
for the detection of unsuspected distant metastases. Although PET FDG has been concordant with the findings of CT and MRI in diagnosing various tumors, FDG also has its drawbacks. For example, a significant amount (>95%) of FDG concentrates in the cytosolic fraction, which results in false-positive lesions, misdiagnosing inflammation and/or infection as tumor recurrence [9] . Additionally, FDG does not provide accurate prediction of therapeutic response. Due to its high brain uptake [10] , FDG radiation dosimetry makes it unsuitable for internal radiotherapy. In addition to the drug distribution, 18 F is inappropriate for internal radiotherapy due to its decay scheme, e.g. all positron, no beta emission. Because it is a cyclotron-produced radiopharmaceutical, there are the additional constraints of high cost and availability of a local cyclotron. On the other hand, radionuclide generator systems that can be produced in a local well-controlled facility can make the cyclotron-produced radiopharmaceutical agents much more accessible and affordable. Such systems are embraced by current FDA procedures and have a long history of successful clinical application. 99m Tc and 68 Ga are Useful Isotopes for Kit-Based Products Development
SELECTION OF ISOTOPES AND BIFUNCTIONAL CHELATORS FOR IMAGING
To develop novel or clinically used tracers, two types of chemistries are frequently used in the preparation of radiotracers: covalent and ionic. In covalent chemistry, either displacement or addition reactions are used to place an isotope in the molecule. The labeled product provides minimal structural alteration, however, the procedure may be lengthy, tedious, with low yield, and costly. Isotopes commonly used in covalent chemistry include 18 F, 123 I, 131 I, 75 Br, 77 Br and 11 C. In addition, PET radiosynthesis must be rapid because the radioisotope will decay during lengthy chemical synthesis and the radiosynthesis process poses a relatively high risk of radiation exposure. Cyclotron-produced tracers are constrained by the availability of local cyclotron and its high cost. Alterna-tively, radionuclide generator systems that can be produced in a well controlled facility have a long history of successful clinical application. A generator uses a parent-daughter nuclide pair wherein a relatively long-lived parent isotope decays to a shortlived daughter isotope that is used for imaging. The parent isotope, which is produced at a cyclotron facility, can be shipped to a clinical site and the daughter isotope eluted on site for clinical use. 68 Ga-based (68-minute half-life) PET agents have significant commercial potential because the isotope can be produced from a 68 Ge generator (275-day half-life) on site and be a convenient alternative to cyclotron-produced PET isotopes, such as 18 F-or 124 I-.
Although the maximum positron energy of 68 Ga (max=1.90 MeV, mean=0.89 MeV) is higher than that of 18 F (max=0.63 MeV, mean=0.25 MeV), a study using Monte Carlo analysis on spatial resolution revealed that under the assumption of 3 mm spatial resolution for PET detectors, the conventional full width at half maximum (FWHM) of 18 F and 68 Ga is indistinguishable in soft tissue (3.01 mm vs. 3.09 mm) [11] . This implies that with the spatial resolution at 5 to 7 mm of current clinical scanners, the imaging quality using 68 Ga-based tracers can be as good as that of 18 F-based agents and has enticed others to investigate the potential of 68 Ga-based imaging agents. For example, carcinoid tumors have been well imaged using 68 Ga-DOTATOC (a somatostatin receptor tracer) and PET [12] .
Due to favorable physical characteristics (360 min half-life, 140keV), easy availability, and low price ($0.21/mCi vs. $50/mCi of 18 F), 99m Tc is an agent of choice for labeling radiopharmaceuticals. 99m Tc can be produced from a 99 Mo generator (2.75-day half-life) on site. Radiolabeling an imaging agent in kit form with 99m Tc or 68 Ga can be easily achieved in high yield. This unique chelator-based imaging technique provides a novel route in a kit formulation, which may make it easier for patients to be evaluated and optimally treated.
Selection of Bifunctional Chelators for Imaging
Several chelators have been reported such as N 4 (e.g. Cyclam-14, DOTA), N 3 S (e.g. MAG-3), N 2 S 2 (e.g. ECD), NS 3, S 4 (e.g. sulfur colloid), diethylenetriamine pentaacetic acid (DTPA), O 2 S 2 (e.g. DMSA), and hydrazinenicotinamide (HYNIC) [5, [13] [14] [15] [16] . Among these chelators, DTPA has faster wash out and forms less stable complexes with 99m Tc. Tc-HYNIC has been shown to be useful in imaging, but labeling HYNIC with 99m Tc requires two chemicals, thiphenylphosphine and tricine, which are inconvenient for the kit preparation. The nitrogen and sulfur combination has been shown to be a stable chelator for 99m Tc-bis-aminoethanethiol tetradentate ligands, also called diaminodithiol compounds, and are known to form very stable Tc(V)O-complexes on the basis of efficient binding of the oxotechnetium group to two thiosulfur and two amine nitrogen atoms. L,L-ethylenedicysteine (EC) is the most successful example of N 2 S 2 chelates [14, [17] [18] [19] . EC can be labeled with both 68 Ga and 99m Tc efficiently with high radiochemical purity and the preparation remains stable for several hours [20] .
Added Value for Chelator-Based Molecular Imaging Agents
In this article we discuss several technologies for the development of new radiotracers using existing pharmaceuticals that alter target functions. Once established, data on the newly developed radiotracers can help in the development of new more effective pharmaceuticals. Once a chelator is conjugated to a "drug" molecule it is considered a new molecule. We use the existing data on the mechanism of action of the "cold" anti-cancer "drug" to support our new "hot" radiopharmaceutical on assessment of target function. In turn, the data we collect on the radiopharmaceutical can help in the design and development of a new, for example more potent, anti-cancer drug, help determine optimal dosage or dose scheduling, and/or assist with assessment of other important end points.
In addition to assessing molecular targets, Re-HEDP) has been demonstrated to be safe and successful in palliating pain [21] . A dose escalation study with 188 Re-HEDP in prostate cancer patients has shown that 3.3 GBq(~90 mCi) dose is the maximum tolerated [22] . Site-specific delivery of anticancer agents or radiation is beneficial for solid tumors and surgically unresectable tumors. 188 Re hydrogel has been demonstrated to be useful against breast tumor growth in animal models [23] . In our laboratory, loco-regional prostate cancer therapy with hydrogel loaded with 188 Re and cisplatin showed tumor cell apoptosis at 48 hrs ( Fig. 1-2) .
RADIOPHARMACEUTICALS IN THE PREDICTION OF THERAPEUTIC RESPONSE
The agents that could provide therapeutic prediction are either labeled molecular biomarkers or radiolabeled drugs. For example, radiolabeled annexin, a biomarker for apoptosis, is useful to evaluate the baseline level of apoptosis, predict the efficacy of therapy based on the detection of treatment-related apoptosis and possibly predict disease progression and prognosis [6, 20, 24] . As another example, assessment of pancreatic beta cell activity by a radiolabeled sulfonylurea receptor agent could provide early diagnosis of pancreatic diseases and monitor drug treatment response on pancreatic beta cells. In the pancreas, the beta cell comprises 60% of all cell types. Glipizide and nateglinide, sulfonylurea receptor agents, stimulate insulin release from pancreatic beta cells, which improves overall glycemic control in type 2 diabetes [25] . The image of 99m Tc-DTPA-glipizide is shown in Fig. 3 . DTPAGlipizide showed better response in lowering glucose level compared to Glipizide (Fig. 4) .
RADIOPHARMACEUTICALS IN DIFFERENTIAL DIAGNOSIS Hypoxia as a Biomarker
It has been well established that hypoxic tumors are known to be resistant to traditional radio-and chemotherapy, resulting in higher local recurrence rates. The ability to quantify in vivo tissue hypoxia via imaging could potentially allow physicians to select patients for additional or alternative treatment regimens that circumvent the ominous impact of hypoxia [4, [26] [27] [28] . For example, metronidazole (MN), a 5-nitroimidazole analogue, has been shown to sensitize only anoxic cells in a dose dependent manner. Although more studies need to be done in cancer patients, clinical studies have shown that 99m Tc-EC-MN, a hypoxic biomarker, is able to differentiate hypoxic regions in stroke patients [29] .
Metabolic Imaging Biomarkers
Glucosamine is a glucose analogue similar to FDG and its cellular uptake is via a glucose transporter process [30] . However, its regulatory products of glucosamine-6-phosphate mediate insulin activation, downstream signaling and translocation, which upregulate mRNA expression and tumor growth [31] . For instance, Sp-1 is one of the known transcription factors whose activity may be post-translationally targeted by glucosamine [32, 33] . Sp-1 binding sites may be present in the promoters of potent angiogenic growth factors such as VEGF and IL-8 and regulate oncogenic Tc-EC-glucosamine is able to differentiate inflammation/infection and tumor growth in animal models and in humans [20, 34, 35] .
Cell Proliferation Biomarkers
Synthesis and biological activity of labeled thymidine or uridine, which were incorporated into DNA/RNA, have been reported [36] [37] [38] [39] . For instance, 3'-deoxy-3'-18 F-fluorothymidine ( 18 F-FLT) is a new tracer which images cellular proliferation by entering the salvage pathway of DNA synthesis. However, DNA incorporation rate of FLT is low and the related chemistry is complex [40, 41] . To continuously explore other purine-based analogues using chelation radiochemistry, we then synthesized 99m Tc-and 68 Ga-EC-guanine (EC-Guan) for evaluation of cell proliferation [42] . 68 Ga-EC-Guan was able to differentiate inflammation versus tumor (Fig. 5) . In vitro cell confluence, cell cycle analysis, cellular uptake and in vivo imaging studies suggest that 99m Ga-EC-Guan may be useful as tumor proliferation imaging agents.
RADIOPHARMACEUTICALS FOR MONITORING TREAT-MENT RESPONSE Amino Acid Transport
The epidermal growth factor receptor (EGFR) is expressed in a variety of human solid tumors. When EGFR is triggered, tyrosine kinase (TK) is phosphorylated and leads to the initiation of receptor-mediated signal transduction, cell proliferation, survival, angiogenesis, and metastasis. TK inhibitors [such as gefitinib (marketed as Iressa), erlotinib (marketed as Tarceva), and imatinib mesylate (marketed as Gleevec)] have shown effectiveness against tumor growth [43] . Radiolabeled amino acids (such as tyrosine and lysine) are involved in protein synthesis via an amino acid transporter [44] [45] [46] , which is suitable to assess the end-point of TK activity. Our results using PET/CT in animal models have demonstrated that tumors can be clearly visualized by 68 Ga-cyclamtyrosine (Fig. 6) . Dynamic PET images have shown that tumor uptake reached a plateau at 3-5 min post-administration of 68 Gacyclam-tyrosine (Fig. 7) .
Development of Hybrid Imaging Agents
The ability to acquire functional and anatomic information in a single scheduled examination offers many clinical and workflow benefits. The successful marriage between PET and CT is making CT almost a standard component of any PET purchase. Despite the attention lavished on PET and PET/CT over the past few years, SPECT remains the bread and butter of the nuclear medicine workload worldwide. Planar imaging in the past with single photon emitting radionuclides has been a suboptimal technique with low diagnostic sensitivity. However, SPECT has improved its sensitivity for detecting deeply seated lesions while still maintaining a significantly lower cost than PET.
Generator-produced isotopes such as 99m Tc-, 188 Re and 68 Ga should be preferred in clinical practice over cyclotron-produced isotopes due to ease of access and lower cost. Nevertheless, SPECT images are inherently susceptible to attenuation artifacts. Differing scatter and absorption of photons between emission and detection can distort the final images, and failure to correct the attenuation along the photon's path can cause spatial misrepresentation. Therefore, nowadays CTderived anatomical maps are being used to correct the attenuation and improve diagnostic accuracy [47] .
Reliable molecular imaging assesses cellular targets and therapeutic response at low cost, aids in the differential diagnosis of tumor versus benign tissue, aids in the prediction or selection of patients who would benefit from a particular regimen, and provides valuable dosimetry for internal radiation therapy. Stimulated by the success of the multi-sliced PET/CT systems, new hybrid SPECT/ CT systems with advanced reconstruction software are being introduced. The new hybrid SPECT/CT systems come complete with an integrated diagnostic-quality CT scanner; these new hybrid SPECT/CT systems hold the potential to further improve attenuation correction and precisely correlate radionuclide signals with anatomic positions [48] [49] [50] [51] [52] [53] . Molecular biological discoveries have great implications for prevention, detection, and targeted therapy. In vivo molecular imaging agents are able to provide cellular and molecular information. The combination of CT morphological/ anatomical information with these new mechanism-based agents should provide for accurate assessment of target function and image-guided therapy. Thus, it would be ideal to develop a molecular imaging agent suitable for PET/CT, SPECT/CT, PET/MRI and SPECT/MRI. The use of hybrid imaging agents should be more beneficial to patients by providing physicians with critical information that in turn could lead to more accurate diagnoses and more effective treatment regimens.
CHALLENGES IN MOLECULAR IMAGING
There are risks for industry to step in for molecular licensing based on patent information alone. Patents regarding molecular imaging technologies tend to review the structure composition, method of production, and potential applications of such technologies, while providing limited clinical information [54, 55] . The regulatory compliance issues for clinic phase I studies are related to chemistry, manufacturing and control (CMC), pharmacology and toxicology. In regards to CMC, some isotopes ( 68 Ga, 188 Re, 61 Cu, 64 Cu) are attractive for chelation, but the validation from laboratory development to clinic grade has not been well addressed. This includes physical (photon energy, mass spectrum) and chemical (metallic form, pH, radiochemical purity) characteristics. The reference cold standard needs be synthesized for radiochemical identity confirmation. In addition to assessment of radiochemical yield, assessment of in vivo stability is equally important. To manufacture an end product for clinical use, the site for current Good Manufacturing Practice (cGMP) (academic vs. industry) needs to be arranged. For pharmacology and toxicology data, drug uptake vs. target validation needs be addressed. In animal models, biodistribution and dosimetry studies need to be performed. The toxicology studies need to be conducted under Good Laboratory Practice (GLP). For angiogenesis imaging, EC-endostatin, EC-CBX and EC-C225 are adequate to assess specific targets. For tumor hypoxia imaging, a classic nitroimidazole agent such as metronidazole is useful to monitor treatment response and may have potential in drug resistance or radioresistance imaging. Our metabolic imaging agent, radiolabeled EC-DG could assess tumor growth. Radiolabeled tyrosine could be used to monitor metabolic kinase activity. All of these functional ligands should provide information for prediction or monitoring treatment response of tumors. Thus, they may improve the diagnosis, planning and monitoring of cancer treatment. Challenges in radio-metallic chemistry promote opportunities in drug development.
CURRENT AND FUTURE DEVELOPMENTS
Currently multiple isotopes and chelators and synthetic techniques are being used by investigators. Without uniformity, it is difficult to draw conclusions regarding the best technology to use. Even if labeling a single molecule, each change in chelator or isotope could lead to changes in the metabolic profile. Ideally, more of the variables would be controlled and deeper testing performed. Due to the wide variety of targets, isotopes, and chelator agents in use, we would recommend that future focus be on the development and universal adoption of accessible, affordable, reproducible, and accountable techniques to assess the relative value of these technologies.
